Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences royalty, contract and other revenues ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K
Latest, FY2025
527
Period ended Dec 31, 2025
Change on a year earlier
+266.0%
144 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Royalty, contract and other revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 527 | +266.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 144 | -20.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 182 | -39.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 299 | +0.7% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 297 | -11.1% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 334 | +1.2% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 330 | -26.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 450 | +1.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 445 | +1.8% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 437 | – | Form 10-K (filed 2019-02-26) ↗ |
Breakdown
What makes up royalty, contract and other revenues ($m)
Cite this data
StockData. (2026). Gilead Sciences Royalty, contract and other revenues ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rev_royalty_contract
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.